You need to enable JavaScript to run this app.
WEBCAST: Understanding the Draft Guidance on Postmarketing Safety Reporting for Combination Products – An Interactive Analysis with FDA and Industry
Amgen
601 13th St NW
Washington
,
District of Columbia
,
USA
,
20005-3807
Advanced therapies/cell and gene therapy
APIs
Biologics/ biosimilars/ vaccines
Biotechnology
Combination products/companion diagnostics
Cosmetics
Diagnostics/IVDs
Digital health/SaMD/AI
Generics
Medical Devices
Nutritional/Natural Health
OTC
Other
Pharmaceuticals